ASTELLAS PHARMA
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
A Study to Assess Intraocular Pressure and Ocular Safety of the Beta-3 Agonist Mirabegron in Research Subjects
- First Posted Date
- 2011-01-27
- Last Posted Date
- 2013-12-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 321
- Registration Number
- NCT01284309
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
A Study in Healthy Young Men to Look at What Drives the Cardiovascular Effects After Dosing With Mirabegron.
Phase 1
Completed
- Conditions
- Healthy VolunteersPharmacodynamics of Mirabegron
- Interventions
- First Posted Date
- 2011-01-27
- Last Posted Date
- 2013-07-03
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 12
- Registration Number
- NCT01284868
A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients
Phase 1
Completed
- Conditions
- Prostate CancerProstate NeoplasmsCastration Resistant Prostate Cancer (CRPC)
- Interventions
- First Posted Date
- 2011-01-27
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 47
- Registration Number
- NCT01284920
Study of an Investigational Drug, ASP3026, in Patients With Advanced Malignancies (Solid Tumors and B-Cell Lymphoma)
Phase 1
Completed
- Conditions
- Advanced MalignanciesPositive for Proto-Oncogene Tyrosine-Protein Kinase ROSB-Cell LymphomaSolid TumorPositive for Anaplastic Lymphoma Kinase
- Interventions
- First Posted Date
- 2011-01-26
- Last Posted Date
- 2016-06-28
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 46
- Registration Number
- NCT01284192
- Locations
- 🇺🇸
Site US184, Sacramento, California, United States
🇺🇸Site US11, Chicago, Illinois, United States
🇺🇸Site US2492, Houston, Texas, United States
A Safety and Pharmacokinetics Study of ASP0456 in Healthy Subjects
- First Posted Date
- 2011-01-20
- Last Posted Date
- 2011-01-20
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 32
- Registration Number
- NCT01279915
A Study to Assess Pharmacokinetic, Pharmacodynamic, Safety and Tolerability of ASKP1240 in de Novo Kidney Transplantation
- First Posted Date
- 2011-01-19
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 50
- Registration Number
- NCT01279538
- Locations
- 🇺🇸
Loyola University Medical Center, Maywood, Illinois, United States
🇺🇸Christ Hospital, Cincinnati, Ohio, United States
🇺🇸University of Cincinnati - University Internal Medicine Associates, Cincinnati, Ohio, United States
A Study to Evaluate Efficacy of YM060 on Diarrhea-predominant Irritable Bowel Syndrome (D-IBS) in Female Patients
- First Posted Date
- 2011-01-11
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 409
- Registration Number
- NCT01274000
Single-dose Study to Assess Pharmacokinetics of Solifenacin Succinate Suspension in Children and Adolescents
Phase 1
Completed
- Conditions
- Urinary Bladder, Overactive
- Interventions
- First Posted Date
- 2010-12-17
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 42
- Registration Number
- NCT01262391
Study to Find Maintenance Dose for Periodic Administration of ASP3550
- First Posted Date
- 2010-12-16
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 155
- Registration Number
- NCT01261572
Safety and Effectiveness of Repeated Administration of QUTENZA Patches for Treatment of Pain Caused by Nerve Damage
- First Posted Date
- 2010-12-02
- Last Posted Date
- 2018-04-19
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 306
- Registration Number
- NCT01252160
© Copyright 2025. All Rights Reserved by MedPath